FDA grants breakthrough therapy designation to Usona Institute’s psilocybin for major depressive disorder

This article was originally published here

Breakthrough Therapy Designation establishes FDA’s organizational commitment to promoting an efficient development program for psilocybin in MDD. The designation of psilocybin as a Breakthrough Therapy for MDD acknowledges

The post FDA grants breakthrough therapy designation to Usona Institute’s psilocybin for major depressive disorder appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply